For the half-year to 31 December 2015, the IPKat's regular team is supplemented by contributions from guest bloggers Jani Ihalainen, Nikos Prentoulis and Mark Schweizer.

Birgit Clark is on Sabbatical till the end of the year

Regular round-ups of the previous week's blogposts are kindly compiled by Alberto Bellan.

Friday, 1 December 2006


Reuters reports that Thailand is to begin making its own generic version of the AIDs drug Efavirenz under a compulsory licence from June 2007. This has angered the patent-owner, Merck, which has said that it has not been consulted. The company will receive a 0.5% royalty on all sales, which will be made at approximately half the usual selling price. Thailand currently have 580,000 people suffering from HIV/AIDs.

The IPKat says that this could prove an important test for the meaning of the TRIPs national emergencies exception.

No comments:

Subscribe to the IPKat's posts by email here

Just pop your email address into the box and click 'Subscribe':